Table 2.
Roles of the exosomal miRNA cargo in thoracic cancers.
| Exosomal Component | Origin of the Exosomes | Role | Cancer | Ref. |
|---|---|---|---|---|
| miR-23a | Hypoxic LC cell lines | Targets CD107a NK inhibition |
LC | [36] |
| Hypoxic lung cancer cells | Angiogenesis vascular permeability |
LC | [46] | |
| A549 cells | EMT | LC | [47] | |
| miR-21 | CSE-HBE cells | Angiogenesis | LC | [48] |
| miR-210 | Lung AC cells | Angiogenesis | LC | [49] |
| miR-23a | Hypoxic LC cells | Angiogenesis | LC | [46] |
| miR-96 | Serum | Metastasis | LC | [50] |
| miR-106b | Serum | Metastasis | LC | [51] |
| miR-199a-3p, miR-210-3p, miR-5100 | Plasma | Metastasis | LC | [52] |
|
miR-378a, miR-379, miR-139-5p, miR-200b-5p
miR-151a-5p, miR-30a-3p, miR-200b-5p, miR-629, miR-100, miR-154-3p |
Plasma | Dividing LC from non-LC Dividing AC from granuloma |
LC | [53] |
|
miR-205-5p
miR-200b |
Pleural effusions | Diagnosis | LC | [54] |
| miR-100-5p | A549 cells | Cisplatin resistance | LC | [55] |
| miR-425-3p | A549 cells | Cisplatin resistance | LC | [56] |
| miR-21 | HCC827 | Gefitinib resistance | LC | [57] |
| miR-214 | PC-9 cells | Gefitinib resistance | LC | [58] |
| miR-499a-5p | Highly metastatic LC cell lines | EMT, proliferation, migration | AD | [59] |
| miR-505-5p | Plasma | Diagnosis | AD | [60] |
| miR-660-5p | Plasma | Metastasis | NSCLC | [61] |
| miR-17-3p, miR-21, miR-106a, miR-146, miR-155, miR-191, miR-192, miR-203, miR-205, miR-210, miR-212, miR-214 | Plasma | Diagnosis | NSCLC | [62] |
| miR-126, miR-144, miR-302a and miR-302c | Plasma BAL |
Diagnosis | NSCLC | [63] |
| miR-1-3p, miR-144-5p, miR-150-5p | BAL | Diagnosis | NSCLC | [64] |
| miR-17-5p | Serum | Diagnosis | NSCLC | [65] |
|
Let-7b, Let-7e, miR-23a-3p, miR-486
miR-181-5p,30a-3p, 30e-3p, 361-5p miR-10b-5, 15b-5p, 320b |
Plasma | Diagnosis Diagnosis Diagnosis |
NSCLC | [66] |
| Let-7f, miR-20b, miR-30e-3p, miR-223 and miR-301 | Plasma | Prognosis | NSCLC | [67] |
| miR-23b-3p, miR-10b-5p and miR-21-5p | Plasma | Overall survival | NSCLC | [50] |
| miR-378 | Serum | Overall survival | NSCLC | [68] |
| miR-21, miR-4257 | Plasma | Prognosis/recurrence | NSCLC | [69] |
| miR-199-a, miR-200c-3p, miR-21-5p, miR-28-5p, miR-30e-3p | Plasma | Prediction of PD1/PD-L1 treatment | NSCLC | [70] |
| miR-146a-5p | Serum | Prediction of cisplatin response | NSCLC | [71] |
| miR-221, miR-222 | Plasma | Prediction of osimertinib response | NSCLC | [72] |
| miR-16-5p | Diagnosis | MPM | [73] | |
|
miR-103a-3p
miR-30e-3p |
Plasma | Discriminate MPM from non-MPM with PAE | MPM | [74] |
NSCLC: non-small cell lung cancer, LC: lung cancer, AD: adenocarcinoma, SCC: squamous cell carcinoma, CSE-HBE: cigarette smoke extract transformed human bronchial epithelial cells, MPM: malignant pleural mesothelioma.